Theracryf Plc

Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II clinical trials for metastatic breast cancer. Additionally, SFX-01 is in Phase I trials for neurodevelopmental conditions and glioblastoma, and is undergoing preclinical investigation for rhabdomyosarcoma. The company's pipeline also includes an orexin 1 antagonist, which is in the late preclinical stage for addressing addiction and anxiety, alongside an atypical dopamine transporter inhibitor (DAT) at a similar development stage, targeting fatigue and narcolepsy. Incorporated in 2014 and headquartered in Nether Alderley, United Kingdom, the company rebranded from Evgen Pharma plc to Theracryf Plc in April 2024.